Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
Palvella Therapeutics appointed Matt Pauls, J.D., M.B.A., to its Board of Directors, leveraging his more than 25 years of experience in developing and commercializing therapies for rare diseases. Mr. Pauls currently serves as Chair and CEO of Savara Inc. and previously held leadership roles at Insmed Incorporated and Strongbridge Biopharma, where he led commercial launches and an IPO.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.